FH
Foghorn Therapeutics Inc.
FHTX · NASDAQ
$2.00 +0.50% (+$0.01)
1M -55.68%
Market Cap $116.8M
P/E Ratio -
Div. Yield -
ROE -
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
55 /100
Fair P/S 3.18x
P/E N/A
EV/EBITDA N/A
Growth
96 /100
Growing Rev. growth 17.14%
EPS growth N/A
FCF growth N/A
Profitability
17 /100
Weak Gross margin 42.73%
Net margin 175.78%
Op. margin 186.38%
Quality
3 /100
Poor ROIC 44.00%
ROA 31.75%
Asset turnover 0.18x
Debt
100 /100
Low Current ratio 3.36x
Debt/Equity N/A
Int. coverage N/A
Stability
31 /100
Unstable Beta 2.86x
Rev. volatility 56.38%
EPS volatility 11.11%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FHTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adrian H. Gottschalk
Employees
106
Headquarters
Watertown
Upcoming events
04 NOV
Earnings
Upcoming earnings report